Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 19, 2025

Designing for Containment: Strategies for Safe and Compliant Cleanroom Facilities

Author(s)G-CON

In this technical paper, Pete Makowenskyj, Sr. Director of Design Consulting at G-CON, explains how cleanroom facilities handling hazardous materials must balance patient safety, product sterility, and operator protection. The paper outlines the regulatory landscape, highlighting gaps between contamination-control guidance and containment requirements for high-risk agents such as ADCs, radiopharmaceuticals, and spore-forming organisms. It details key design considerations—including pressure schemes, HVAC zoning, filtration, and decontamination strategies—that ensure safe, compliant operations. The paper also emphasizes the value of prefabricated cleanroom solutions for achieving tighter environments, flexibility, and future-proofing.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.